Ozempic Wegovy Mounjaro Zepbound

GLP-1 Coverage Guide

GLP-1 receptor agonists are among the most prescribed and most expensive drugs in America. Coverage varies dramatically by plan type, diagnosis, and state. Here is what you need to know.

Drug Comparison

Ozempic Wegovy Mounjaro Zepbound
Active Ingredient Semaglutide Semaglutide Tirzepatide Tirzepatide
FDA Approved For Type 2 Diabetes Chronic Weight Management Type 2 Diabetes Chronic Weight Management
Medicare Part D Covered (diabetes) Not covered (weight loss) Covered (diabetes) Not covered (weight loss)
Typical Formulary Tier Tier 3 (Preferred Brand) N/A or Tier 5 Tier 3 (Preferred Brand) N/A or Tier 5
Prior Auth Required Usually yes If covered, yes Usually yes If covered, yes
Avg Monthly (with insurance) $25 - $150 $300 - $1,350 $25 - $150 $300 - $1,060
Avg Monthly (without insurance) $900 - $1,100 $1,300 - $1,400 $1,000 - $1,200 $1,000 - $1,100

Costs are approximate and vary by plan, pharmacy, and region. Manufacturer savings programs may reduce out-of-pocket costs for eligible patients.

Coverage by Plan Type

GLP-1 coverage depends heavily on your insurance type, your diagnosis, and in some cases your state.

Medicare Part D

65+ / Disabled

For diabetes: Ozempic and Mounjaro are covered under most Part D formularies when prescribed for Type 2 diabetes. Expect Tier 3 placement with prior authorization.

For weight loss: Medicare is statutorily prohibited from covering drugs prescribed solely for weight loss. Wegovy and Zepbound are not covered under Part D for obesity, regardless of BMI or comorbidities.

What could change: The Treat and Reduce Obesity Act (TROA) has been reintroduced in Congress and would lift this exclusion. No timeline for passage as of early 2026.

ACA Marketplace Plans

Individual / Family

Coverage varies dramatically by insurer and plan tier. Silver and Gold plans are more likely to include GLP-1s for diabetes. Weight management coverage is rare but growing.

  • Diabetes indication: most plans cover with prior authorization
  • Weight loss indication: roughly 20-30% of marketplace plans include some GLP-1 coverage for obesity
  • Expect Tier 4-5 placement with significant cost sharing ($200-$500/month)
  • Check your plan's formulary before open enrollment

Employer-Sponsored Plans

Group Coverage

Employer plans are the most likely to cover GLP-1s for both diabetes and weight management, but many are adding restrictions as costs surge.

  • Large employers (500+ employees): ~60% now cover GLP-1s for weight loss
  • Mid-size employers: coverage is growing but cost concerns are creating carve-outs
  • Some employers require enrollment in a weight management program alongside the prescription
  • PBM formulary decisions drive most employer plan coverage

Medicaid

State Programs

Medicaid coverage for GLP-1s is entirely state-dependent. Most states cover for diabetes. Coverage for weight management is expanding but inconsistent.

  • All 50 states cover GLP-1s for Type 2 diabetes with prior authorization
  • Approximately 20 states have added some form of weight management coverage
  • State Medicaid preferred drug lists (PDLs) may favor one GLP-1 over another
  • Supplemental rebate agreements between states and manufacturers affect availability

The Weight Loss Coverage Gap

Medicare's statutory exclusion of weight loss drugs creates a two-tier system. Seniors with obesity-related conditions who could benefit from GLP-1s face $12,000-$16,000 in annual out-of-pocket costs, while those with a diabetes diagnosis pay a fraction of that for the same molecule.

The Anti-Obesity Medication Act (previously TROA) would require Medicare to cover FDA-approved anti-obesity medications. The bill has bipartisan support but faces cost concerns: CBO estimates covering GLP-1s for weight loss in Medicare could cost $30-$50 billion over 10 years.

Current workarounds: Some patients obtain coverage through off-label diabetes-related diagnoses, manufacturer patient assistance programs, or compounding pharmacies offering semaglutide at lower cost (though FDA has raised safety concerns about compounded versions).

Prior Authorization Requirements

Nearly all plans require prior authorization for GLP-1 prescriptions. These are the typical criteria insurers evaluate.

1
Confirmed diagnosis of Type 2 diabetes (for Ozempic/Mounjaro) or BMI over 30, or BMI over 27 with at least one weight-related comorbidity (for Wegovy/Zepbound)
2
Failed trial of first-line therapy. For diabetes: typically metformin for 3+ months with inadequate glycemic control (A1C above 7%). For weight loss: documented lifestyle intervention (diet and exercise program)
3
A1C threshold met (diabetes). Most plans require A1C of 7.0% or higher despite metformin. Some require 8.0%+ for approval
4
Prescriber qualification. Must be prescribed by an endocrinologist, PCP, or other qualified provider. Some plans require specialist referral
5
Ongoing compliance documentation. Many plans require reauthorization every 6-12 months with evidence of clinical response (A1C improvement, weight loss, or both)
6
No contraindicated conditions. Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome is a contraindication for all GLP-1 agonists

Frequently Asked Questions

What is a formulary?
A formulary is a list of prescription drugs covered by a health insurance plan. Plans organize drugs into tiers, with lower tiers generally having lower out-of-pocket costs. Not all drugs are on every formulary, and tier placement varies by plan.
What do drug tiers mean?
Most plans use a tier system: Tier 1 (preferred generics, lowest cost), Tier 2 (non-preferred generics or preferred brands), Tier 3 (non-preferred brands, higher cost), Tier 4 or 5 (specialty drugs, highest cost). Your copay or coinsurance depends on which tier your drug is placed on.
What is prior authorization?
Prior authorization (PA) is a requirement from your insurance plan that your doctor must get approval before the plan will cover a specific drug. The plan reviews whether the drug is medically necessary based on your diagnosis, treatment history, and their clinical criteria.
What is step therapy?
Step therapy requires you to try one or more less expensive drugs before your plan will cover a more expensive drug. For example, a plan might require you to try metformin before covering a GLP-1 drug like Ozempic. Your doctor can request an exception if there is a clinical reason to skip a step.
How do I know if my drug is covered by my plan?
Check your plan's formulary, which lists all covered drugs and their tier placement. You can usually find it on your insurance company's website. InsureWith.ai aggregates formulary data from Medicare Part D, ACA Marketplace plans, and major commercial insurers so you can search across plans in one place.
What should I do if my drug is denied coverage?
First, ask your doctor for the specific denial reason. Common paths forward: request a formulary exception from your plan (your doctor submits a letter of medical necessity), appeal the denial through your plan's formal appeals process, ask your doctor about therapeutic alternatives that are on formulary, or check if the drug manufacturer offers a patient assistance program.
What is the difference between a copay and coinsurance?
A copay is a fixed dollar amount you pay for a prescription (e.g., $10 for a generic). Coinsurance is a percentage of the drug's cost (e.g., 20% of a $500 specialty drug = $100). Plans may use copays for lower tiers and coinsurance for higher tiers and specialty drugs.
How often does formulary data change?
Plans can update their formularies throughout the year. Major changes typically happen at the start of the plan year (January for Medicare, plan renewal date for employer plans). Mid-year changes are less common but can occur. CMS requires Part D plans to provide 60 days notice before removing a drug or moving it to a less favorable tier.

Compare GLP-1 pricing across pharmacies

Search drug prices on RxSaver.ai
InsureWith Assistant
Hi! I can help you understand drug coverage, formulary tiers, prior authorization, and more. What would you like to know?